BioSpace News Archive

Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced that it will report second quarter 2020 financial results on Monday, August 10, 2020. Recro’s management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, August 10

PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its Senior Vice President of Corporate and Patient Relations, Mary Frances Harmon, has been named to PharmaVOICE magazine’s annual list of the most inspiring people in the life sciences industry

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that it has entered into a clinical trial collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to evaluate the combination of patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), and TAGRISSO (osimertinib), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), in patients wi

– Collaborations announced with AVROBIO and Beam Therapeutics to evaluate potential usage of MGTA-117 in conditioning patients in gene therapy and gene editing settings, respectively — – MGTA-145 to move into Phase 2 trials in autologous and allogeneic transplant in 2020, including allogeneic study in newly announced collaboration with National Marrow Donor Program® (NMDP)/Be The Match® - – Ended quarter with $176.5 million in cash, cash equivale

-Approval of ADC Utilizing Seattle Genetics’ Proprietary Technology Generates $20 Million Milestone Payment and Future Royalties on Worldwide Net Sales- BOTHELL, Wash.--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKline’s (GSK) BLENREP™ (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle G

The Penn State Microbiome Center and General Automation Lab Technologies announced their collaboration to advance plant pathology, environmental microbiology and human gut microbiome studies.

Halberd Corp. confirmed the signing of Dr. Gregory George as a member of the Scientific Advisory Board.

TR-1: Standard form for notification of major holdings

Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that DNL151 has been selected to progress into late stage studies in Parkinson’s disease patients with a kinase activating mutation in LRRK2 and in sporadic Parkinson’s disease patients

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (“Regulus”), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 2:20 PM EDT.